Revolution Medicines, Inc.
Foreign stocks · NASDAQ · Healthcare · Pharmaceuticals
Develops cancer drugs targeting RAS genes, which drive many types of cancer. The company is still in clinical trials and has no drug sales revenue yet
Investors in Thailand can buy RVMD through 7 mutual funds open to retail investors. Most of them (7 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds RVMD.
| Fund | RVMD weight | How it invests | 1-year return |
|---|---|---|---|
 LHLONGEVITYLH LONGEVITY HEALTHCARE FUND | 5.42% | Via CANC | N/A |
 ASP-IHEALTHAsset Plus Innovative Healthcare Fund | 4.36% | Via several master funds (JHHBIU2 LX, ARKG US) | +20.72% |
 DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND | 4.28% | Via Janus Henderson Horizon Biotechnology Fund | +2.88% |
 ONE-DISC-ASSFONE DISCOVERY FUND | 2.61% | Via Baillie Gifford Worldwide Discovery Fund | −1.98% |
| ONE-DISCRMF-AONE DISCOVERY RETIREMENT MUTUAL FUND | 2.59% | Via Baillie Gifford Worldwide Discovery Fund | −2.08% |
 BCAP-XHEALTHBCAP NEXT GEN Health Fund | 2.03% | Via several master funds | +17.62% |
 KT-USSM-AKTAM US Small Cap Equity Passive Fund | 0.52% | Via VB | +12.60% |
Yearly average over the last 4 years · Latest annual sales 0.0M USD
For every 100 dollars of sales, about 0 dollars is left as net profit
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
Now 9.5% below its 1-year high
| Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | 29.0M USD | 35.0M USD | 12.0M USD | 0.0M USD | 0.0M USD |
| Operating profit | −188.0M USD | −258.0M USD | −487.0M USD | −690.0M USD | −1.2B USD |
| Net profit | −187.0M USD | −249.0M USD | −436.0M USD | −600.0M USD | −1.1B USD |
| EPS (diluted) | −0.86 | −1.54 | −1.93 | −3.58 | −5.95 |
| Operating margin | −648.3% | −737.1% | −4,058.3% | 0.0% | 0.0% |
| Net margin | −644.8% | −711.4% | −3,633.3% | 0.0% | 0.0% |
| Operating cash flow | −147.0M USD | −224.0M USD | −351.0M USD | −557.0M USD | −898.0M USD |
| Free cash flow | −154.0M USD | −235.0M USD | −358.0M USD | −568.0M USD | −914.0M USD |
| Total assets | 738.0M USD | 812.0M USD | 2.1B USD | 2.6B USD | 2.4B USD |
| Total liabilities | 135.0M USD | 127.0M USD | 236.0M USD | 293.0M USD | 723.0M USD |
| Shareholders' equity | 603.0M USD | 685.0M USD | 1.8B USD | 2.3B USD | 1.6B USD |
| Period | SMA | EMA | Price vs line |
|---|---|---|---|
| 10 days | 189.77 | 191.87 | Above |
| 20 days | 189.58 | 192.10 | Above |
| 50 days | 198.22 | 193.88 | Above |
| 100 days | 193.81 | 185.78 | Above |
| 200 days | 157.15 | 160.70 | Above |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 56.78 | Up |
| MACD(12,26) | −1.17 | Down |
| ADX(14) | 17.11 | Neutral |
| ATR(14) % of price | 2.05 | Neutral |
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
ONEAM2LHFUND1ASSETFUND1DAOLINV1BBLAM1KTAM1| Fund | RVMD weight | Master fund | 1-year return | TER |
|---|---|---|---|---|
| LHLONGEVITY | 5.42% | CANC | N/A | 2.10% |
| ASP-IHEALTH | 4.36% | several master funds (JHHBIU2 LX, ARKG US) | +20.72% | 2.83% |
| DAOL-GIHEALTH | 4.28% | Janus Henderson Horizon Biotechnology Fund | +2.88% | 2.32% |
| ONE-DISC-ASSF | 2.61% | Baillie Gifford Worldwide Discovery Fund | −1.98% | 1.80% |
| ONE-DISCRMF-A | 2.59% | Baillie Gifford Worldwide Discovery Fund | −2.08% | 1.90% |
| BCAP-XHEALTH | 2.03% | several master funds | +17.62% | 1.23% |
| KT-USSM-A | 0.52% | VB | +12.60% | 1.08% |
| Master fund | Thai funds using this route | Master fund's RVMD weight |
|---|---|---|
| Baillie Gifford Worldwide Discovery Fund | 2 | 2.61% |
| Tema Oncology ETF | 1 | 5.42% |
| several master funds (JHHBIU2 LX, ARKG US) | 1 | 4.36% |
| Janus Henderson Horizon Biotechnology Fund | 1 | 4.28% |
| several master funds | 1 | 2.03% |
| Vanguard Morningstar Small-Cap ETF | 1 | 0.52% |
